2020
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal Of Urology 2020, 205: 769-779. PMID: 33021440, DOI: 10.1097/ju.0000000000001362.Peer-Reviewed Original ResearchConceptsGrade Group 2 diseaseProstate-specific antigen reductionGrade group 2Whole gland ablationTransurethral ultrasound ablationAntigen reductionMagnetic resonance imagingProstate cancerGroup 2Gland ablationMagnetic resonance imaging-guided transurethral ultrasound ablationGrade 3 adverse eventsResonance imagingTarget volumeEvidence of cancerUltrasound ablationIntermediate-risk diseaseRisk prostate cancerProspective multicenter trialMedian prostate volumeLocalized prostate cancerMedian treatment delivery timeTreatment delivery timeMagnetic resonancePrimary endpoint
2017
Therapeutic Ultrasound and Prostate Cancer
Sundaram KM, Chang SS, Penson DF, Arora S. Therapeutic Ultrasound and Prostate Cancer. Seminars In Interventional Radiology 2017, 34: 187-200. PMID: 28579687, PMCID: PMC5453783, DOI: 10.1055/s-0037-1602710.Peer-Reviewed Original ResearchProstate cancerIntermediate-risk prostate cancerRisk prostate cancerAdverse event ratesInvasive alternative treatmentExternal beam radiotherapyDefinitive therapyAdverse eventsUrinary incontinenceClinical efficacyErectile dysfunctionRadical prostatectomyClinical trialsFocal therapyAlternative treatmentFDA approvalEvent ratesUltrasound ablationMRI guidanceTherapeutic ultrasoundUltrasound approachTherapyHIFU deviceCancerUltrasound